Hemab Therapeutics Holdings, Inc. Common Stock cash flow to debt ratio of -5.04K% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Hemab Therapeutics Holdings, Inc. Common Stock has insufficient data to evaluate this check.

Hemab Therapeutics Holdings, Inc. Common Stock has insufficient data to evaluate this check.

Hemab Therapeutics Holdings, Inc. Common Stock has insufficient data to evaluate this check.

Hemab Therapeutics Holdings, Inc. Common Stock has a net cash position, so leverage is healthy.

Hemab Therapeutics Holdings, Inc. Common Stock earns at least as much interest as it pays. Interest obligations are fully covered.

Hemab Therapeutics Holdings, Inc. Common Stock has insufficient data to evaluate this check.

Hemab Therapeutics Holdings, Inc. Common Stock has insufficient data to evaluate this check.

Hemab Therapeutics Holdings, Inc. Common Stock's return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Hemab Therapeutics Holdings, Inc. Common Stock's return on equity of 36.18%, is higher than 15.00%, indicating good performance

Hemab Therapeutics Holdings, Inc. Common Stock's operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Hemab Therapeutics Holdings, Inc. Common Stock has insufficient public price history to evaluate earnings stability.

Hemab Therapeutics Holdings, Inc. Common Stock has negative free cash flow, indicating the company is burning cash rather than generating it

Hemab Therapeutics Holdings, Inc. Common Stock has negative free cash flow, indicating cash burn

Hemab Therapeutics Holdings, Inc. Common Stock has insufficient data to evaluate this check.

Hemab Therapeutics Holdings, Inc. Common Stock has insufficient data to evaluate this check.

ROIC -37.82% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Hemab Therapeutics Holdings, Inc. Common Stock has insufficient revenue history to calculate 3-year revenue CAGR.

Hemab Therapeutics Holdings, Inc. Common Stock has insufficient public price history to evaluate revenue consistency.

Hemab Therapeutics Holdings, Inc. Common Stock has insufficient public price history to evaluate ROE consistency.

Hemab Therapeutics Holdings, Inc. Common Stock has insufficient data to evaluate this check.

Hemab Therapeutics Holdings, Inc. Common Stock has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Hemab Therapeutics Holdings, Inc. Common Stock is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Hemab Therapeutics Holdings, Inc. Common Stock has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Hemab Therapeutics Holdings, Inc. Common Stock has insufficient data to evaluate this check.

Hemab Therapeutics Holdings, Inc. Common Stock has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Hemab Therapeutics Holdings, Inc. Common Stock has negative shareholder equity; price-to-book is not meaningful and the check fails

Hemab Therapeutics Holdings, Inc. Common Stock has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue